<?xml version='1.0' encoding='utf-8'?>
<document id="24927617"><sentence text="Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin."><entity charOffset="68-78" id="DDI-PubMed.24927617.s1.e0" text="telaprevir" /><entity charOffset="83-94" id="DDI-PubMed.24927617.s1.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.24927617.s1.e0" e2="DDI-PubMed.24927617.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24927617.s1.e0" e2="DDI-PubMed.24927617.s1.e1" /></sentence><sentence text="A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir"><entity charOffset="90-99" id="DDI-PubMed.24927617.s2.e0" text="ribavirin" /><entity charOffset="126-136" id="DDI-PubMed.24927617.s2.e1" text="telaprevir" /><pair ddi="false" e1="DDI-PubMed.24927617.s2.e0" e2="DDI-PubMed.24927617.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24927617.s2.e0" e2="DDI-PubMed.24927617.s2.e1" /></sentence><sentence text=" The patient also received simvastatin"><entity charOffset="27-38" id="DDI-PubMed.24927617.s3.e0" text="simvastatin" /></sentence><sentence text=" One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed rhabdomyolysis" /><sentence text=" At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected"><entity charOffset="14-25" id="DDI-PubMed.24927617.s5.e0" text="simvastatin" /></sentence><sentence text=" The creatine kinase peaked at 62,246 IU/L and the patient was treated with intravenous normal saline"><entity charOffset="5-13" id="DDI-PubMed.24927617.s6.e0" text="creatine" /></sentence><sentence text=" The patient's renal function remained unaffected" /><sentence text=" Fourteen days after hospitalization, creatine kinase level had returned to 230 IU/L and the patient was discharged"><entity charOffset="38-46" id="DDI-PubMed.24927617.s8.e0" text="creatine" /></sentence><sentence text=" Telaprevir was considered the probable causative agent of an interaction with simvastatin according to the Drug Interaction Probability Scale"><entity charOffset="1-11" id="DDI-PubMed.24927617.s9.e0" text="Telaprevir" /><entity charOffset="79-90" id="DDI-PubMed.24927617.s9.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.24927617.s9.e0" e2="DDI-PubMed.24927617.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24927617.s9.e0" e2="DDI-PubMed.24927617.s9.e1" /></sentence><sentence text=" The interaction is due to inhibition of CYP3A4-mediated simvastatin clearance"><entity charOffset="57-68" id="DDI-PubMed.24927617.s10.e0" text="simvastatin" /></sentence><sentence text=" Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood"><entity charOffset="1-12" id="DDI-PubMed.24927617.s11.e0" text="Simvastatin" /></sentence><sentence text=" In conclusion, with this case we illustrate that telaprevir as well as statins are susceptible to clinical relevant drug-drug interactions"><entity charOffset="50-60" id="DDI-PubMed.24927617.s12.e0" text="telaprevir" /></sentence><sentence text="" /></document>